Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) Stock Overview
Explore Aclaris Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
352.1M
P/E Ratio
-2.86
EPS (TTM)
$-1.58
ROE
-1.03%
ACRS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Aclaris Therapeutics, Inc. (ACRS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.13.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.86 and a market capitalization of 352.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.